Greg Zante Viking Therapeutics, Inc. (VKTX) insider trading activity

Greg Zante is Chief Financial Officer of Viking Therapeutics, Inc.. Currently has a direct ownership of 168,660 shares of VKTX, which is worth approximately $5.39 Million. The most recent transaction as insider was on Apr 03, 2023, when has been sold 55,166 shares (Common stock, par value $0.00001 per share) at a price of $17.57 per share, resulting in proceeds of $969,266. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 169K

2.06% 3M change

3.54% 12M change

Total Value Held $5.39 Million

GREG ZANTE Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 03 2023	SELL Payment of exercise price or tax liability	$969,266 $17.57 p/Share	55,166 Reduced 26.98%	149,279 Common stock, par valu...
Apr 03 2023	BUY Exercise of conversion of derivative security	$240,178 $7.77 p/Share	30,911 Added 14.75%	178,689 Common stock, par valu...
Apr 03 2023	BUY Grant, award, or other acquisition	-	56,667 Added 21.7%	204,445 Common stock, par valu...
Mar 30 2023	SELL Open market or private sale	$2,227,493 $17.0 p/Share	131,029 Reduced 47.0%	147,778 Common stock, par valu...
Mar 30 2023	BUY Exercise of conversion of derivative security	$585,937 $6.25 p/Share	93,750 Added 25.16%	278,807 Common stock, par valu...
Jan 04 2023	SELL Payment of exercise price or tax liability	$174,361 $8.42 p/Share	20,708 Reduced 10.06%	185,057 Common stock, par valu...
Jan 03 2023	SELL Payment of exercise price or tax liability	$203,909 $8.52 p/Share	23,933 Reduced 10.42%	205,765 Common stock, par valu...
Jan 03 2023	BUY Grant, award, or other acquisition	-	90,667 Added 28.3%	229,698 Common stock, par valu...
Dec 30 2022	SELL Payment of exercise price or tax liability	$185,151 $9.4 p/Share	19,697 Reduced 12.41%	139,031 Common stock, par valu...
Dec 30 2022	BUY Grant, award, or other acquisition	-	20,233 Added 11.31%	158,728 Common stock, par valu...
Jan 04 2022	SELL Payment of exercise price or tax liability	$40,818 $4.62 p/Share	8,835 Reduced 6.09%	136,304 Common stock, par valu...
Jan 03 2022	SELL Payment of exercise price or tax liability	$15,113 $4.88 p/Share	3,097 Reduced 3.26%	91,806 Common stock, par valu...
Jan 03 2022	BUY Grant, award, or other acquisition	-	53,333 Added 26.87%	145,139 Common stock, par valu...
Sep 28 2021	SELL Payment of exercise price or tax liability	$14,989 $6.5 p/Share	2,306 Reduced 2.38%	94,485 Common stock, par valu...
Sep 28 2021	BUY Grant, award, or other acquisition	-	6,667 Added 6.44%	96,791 Common stock, par valu...
Jan 19 2021	SELL Payment of exercise price or tax liability	$5,397 $6.68 p/Share	808 Reduced 0.89%	89,751 Common stock, par valu...
Jan 04 2021	SELL Payment of exercise price or tax liability	$16,165 $5.8 p/Share	2,787 Reduced 2.99%	90,559 Common stock, par valu...
Jan 04 2021	BUY Grant, award, or other acquisition	-	71,450 Added 43.36%	93,346 Common stock, par valu...

Greg Zante

Chief Financial Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VKTX shares.

Notify only if

Value

Insider Trading

Get notified when an Viking Therapeutics, Inc. insider buys or sells VKTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Viking Therapeutics, Inc.

Track Activities on VKTX

Account